Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 16 Nov 2026

BIOCON, full dossier

Biocon announced that the US Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab).

4 publishers have reported this development. Each act of reporting is below, cited.

The record

Biocon announced that the US Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab).

Biopharmaceutical company Biocon Ltd received approval from the US Food and Drug Administration (FDA) for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, used in the treatment of HER2-positive breast cancer.

livemint.com16 Nov 2026

Biocon secured US Food and Drug Administration (FDA) approval for Pebrilzo, a biosimilar to the cancer drug Perjeta.

cnbctv18.com16 Nov 2026

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.